Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Tabelecleucel |
Synonyms | |
Therapy Description |
Tabelecleucel (ATA129) is a preparation of donor-derived EBV-specific cytotoxic T-cells, which may decrease growth of EBV-positive tumors (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tabelecleucel | ATA129|ATA 129|EBV-CTL|Tab-cel | Tabelecleucel (ATA129) is a preparation of donor-derived EBV-specific cytotoxic T-cells, which may decrease growth of EBV-positive tumors (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03394365 | Phase III | Tabelecleucel | Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE) | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS | 0 |